The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis

✍ Scribed by Laura J. Savage, Dennis G. McGonagle

• Book ID: 120730060
• Publisher: Springer Healthcare Communications
• Year: 2013
• Tongue: English
• Weight: 486 KB
• Volume: 3
• Category: Article
• ISSN: 2195-5840
• DOI: 10.1007/s13554-013-0010-0

✦ Synopsis

The therapy of psoriatic arthritis (PsA) has blossomed in the past decade. Inhibition of tumor necrosis factor (TNF) has been at the fore of this approach and has paved the way for the investigation of many other potential pro-inflammatory and signaling pathways. Most of the initial studies of TNF inhibitors in PsA have been conducted in specific populations, largely focusing on those with established, peripheral joint disease. That said, in excess of 10 years’ worth of real world clinical experience has led to increased confidence in the wider use of these agents. We are now faced with an exciting time of discovery of many new molecules; these not only include new, large protein biological agents, but also smaller synthetic chemical molecules, many of which can be administered orally. Those currently under development are discussed within this article. Whilst there is scarce data about their real world efficacy and safety profile, it is evident that the therapeutic armamentarium for treating PsA will greatly increase in the foreseeable future and this is anticipated to improve patient outcomes.